Clinical trials: Prostate Cancer Metastatic to Bone
Prostate Cancer With Bone Metastasis
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.
- Trial name
- NCT00241111
- Testing
- zoledronic acid
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Bone Cancer, Bone Metastases
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
The goal of this prospective, non-randomized, single-arm, phase 2 study is to evaluate the safety and effectiveness of this treatment using this ExAblate conformal system in the treatment of pain resulting from metastatic bone…
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01085565
- Testing
- ExAblate 2100
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- InSightec
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Prostatic Neoplasms, Castration-Resistant
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
There are no real-world data that describes how Radium-223 (Ra-223) is being used in combination with abiraterone/enzalutamide (abi/enza) or evidence describing outcomes of this combination usage for the treatment of metastatic…
- Trial name
- NCT03325127
- Testing
- radium Ra 223 dichloride (Xofigo, BAY88-8223), Zytiga, Xtandi
- Sponsor
- Bayer
Prostatic Neoplasms
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
- Trial name
- NCT01810770
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 27 sites in China, Singapore and 2 more
- Volunteers
- 243 people
- Sponsor
- Bayer
Hormone Refractory Prostate Cancer, Bone Metastases
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal…
- Trial name
- ALSYMPCA (NCT00699751)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Best standard of care (BSoC)
- Where
- 134 sites in United States, Australia and 17 more
- Volunteers
- 921 people
- Sponsor
- Bayer
Prostatic Neoplasms, Castration-Resistant
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT02803437
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223)
- Where
- Japan
- Volunteers
- 334 people
- Sponsor
- Bayer
Prostate Cancer Patients With Bone Metastasis
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
- Trial name
- NCT00237159
- Testing
- Zoledronic acid
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Metastatic Castration-Resistant Prostate Cancer
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
In this observational study researchers want to gather more information about bone fractures and survival in castration-resistant prostate cancer (CRPC) patients treated with radium-223 in routine clinical practice in Sweden.
- Trial name
- PRECISE (NCT04256993)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Other standard care
- Where
- Sweden
- Volunteers
- 1,434 people
- Sponsor
- Bayer
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Bone Neoplasms
Bonefos and the Consumption of Analgesics
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
- Trial name
- BICAM (NCT00909142)
- Testing
- Bonefos (Clodronate, BAY94-8393)
- Where
- Czechia
- Volunteers
- 149 people
- Sponsor
- Bayer
Castrate-resistant Prostate Cancer
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
- Trial name
- NCT01824342
- Testing
- Denosumab
- Where
- 9 sites in Czechia, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Amgen